골다공증 및 골감소증 치료제의 치료효과 비교연구
Comparative Study of Anti-osteoporotic Agents in Postmenopausal Women
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to compare retrospectively the efficacy of anti-osteoporotic agents (RAL-Raloxifene60 mg, ALD-weekly alendronate 70 mg, RSD-weekly risedronate 35 mg, AVD3-weekly alendronate 70 mg/vitaminD3 2800IU, IBD-quarterly IV ibandronate 3 mg/3 ml, ZLD-yearly IV zoledronate 5 mg/100 ml) in postmenopausalpatients with osteoporosis or osteopenia. Method: This study retrospectively reviewed medical record and compared thelumbar spine BMD percentage changes of each medicine group one year later from the baseline. 209 patients (27, 50,60, 30, 35, and 7 patients in RAL, ALD, RSD, AVD3, IBD, and ZLD groups, respectively) are within the inclusion criteriafor the study. Results: From baseline to month 12, lumbar spine BMD increased significantly larger with bisphosphonategroups, compared to SERM (p < 0.05). In all bisphosphonate groups, the lumbar spine BMD were increasedsignificantly from baseline. Of the bisphosphonates, the changes from baseline in BMD of IV bisphosphonates weremore larger than those of oral bisphosphonates, and yearly, quarterly bisphosphonates yielded significantly greater BMDgains, compared with weekly bisphosphonate groups (p < 0.05). In addition, patients receiving 70 mg weekly alendronate+vitamin D3 had greater gains in BMD than alendronate Single preparation (p < 0.05). Conclusion: Bisphosphonatesyielded significantly greater BMD gains than SERM. Of the bisphosphonates, the changes from baseline in BMDof yearly, quarterly IV bisphosphonates yielded significantly greater BMD gains, compared with weekly oral bisphosphonategroups. In addition, vitamin D3 plays an significant role in BMD gains.
Abstract
Purpose: The aim of this study was to compare retrospectively the efficacy of anti-osteoporotic agents (RAL-Raloxifene60 mg, ALD-weekly alendronate 70 mg, RSD-weekly risedronate 35 mg, AVD3-weekly alendronate 70 mg/vitaminD3 2800IU, IBD-quarterly IV ibandronate 3 mg/3 ml, ZLD-yearly IV zoledronate 5 mg/100 ml) in postmenopausalpatients with osteoporosis or osteopenia. Method: This study retrospectively reviewed medical record and compared thelumbar spine BMD percentage changes of each medicine group one year later from the baseline. 209 patients (27, 50,60, 30, 35, and 7 patients in RAL, ALD, RSD, AVD3, IBD, and ZLD groups, respectively) are within the inclusion criteriafor the study. Results: From baseline to month 12, lumbar spine BMD increased significantly larger with bisphosphonategroups, compared to SERM (p < 0.05). In all bisphosphonate groups, the lumbar spine BMD were increasedsignificantly from baseline. Of the bisphosphonates, the changes from baseline in BMD of IV bisphosphonates weremore larger than those of oral bisphosphonates, and yearly, quarterly bisphosphonates yielded significantly greater BMDgains, compared with weekly bisphosphonate groups (p < 0.05). In addition, patients receiving 70 mg weekly alendronate+vitamin D3 had greater gains in BMD than alendronate Single preparation (p < 0.05). Conclusion: Bisphosphonatesyielded significantly greater BMD gains than SERM. Of the bisphosphonates, the changes from baseline in BMDof yearly, quarterly IV bisphosphonates yielded significantly greater BMD gains, compared with weekly oral bisphosphonategroups. In addition, vitamin D3 plays an significant role in BMD gains.
참고문헌 (22)
- NIH Consensus Panel on Osteoporosis Prevention, Diagnosis, and Therapy., "Osteoporosis prevention, diagnosis, and therapy", JAMA, 285, pp.785~795 (2001)
- Vestergaard P., "Anti-resorptive therapy for the prevention of postmenopausal osteoporosis : when should treatment begin?", Treat Endocrinol, 4(5), pp.263~277 (2005)
- Tosteson AN., "Therapies for Treatment of Osteoporosis in US Women : Cost-effectiveness and Budget Impact Considerations", Am J Manag Care, 14(9), pp.605~615 (2008)
- "Physician's Guideline for Osteoporosis" (2007), Korean Society for Bone and Mineral Research
- Rakel, "Conn's Current Therapy 2008, 60th ed", pp.149~ (2008)
- Study of an Osteoporosis Management Program in Korea, , Korean Health Promotion Foundation & Ministry of Health and Welfare, ~ (2007)
- Small RE., "Uses and Limitations of Bone Mineral Density Measurements in the Management of Osteoporosis", Med Gen Med, 7(2), pp.3~ (2005)
- Lenchik L., "Executive summary International Society for Clinical Densitometry position development conference", J Clin Densitom, 5, pp.S1~S3 (2002)
- Nancy E., "Lane. Epidemiology, etiology, and diagnosis of osteoporosis", American Journal of Obstetrics and Gynecology, 194, pp.3~11 (2006)
- Lash RW., "Diagnosis and Management of Osteoporosis", Prim Care, 36(1), pp.181~198 (2009)
- Analysis of the health care situation in Korea, , Korea Ministry of Health and Welfare, ~ (2008)
- Study the needs of the elderly living conditions and welfare of Korean society in 2004, "Chung KH", Korea Institute for Health and Social Affairs, 1~192, pp.Policy Report No. 2005-03 (2004)
- Choi JY., "Prevalence and Risk Factors of Osteoporosis and Osteopenia in Korean Women : Cross-sectional Study", J Menopausal Med, 14(1), pp.35~49 (2008)
- "Prevalence of osteoporosis research, to be conducted at the national level" (2008), Centers for Disease Control Press Release
- 윤상호, "폐경 후 골다공증의 최신 치료", Obstetrics & Gynecology Science, 48(4), pp.844~856 (2005), 대한산부인과학회
- Lewiecki EM., "Prevention and treatment of postmenopausal osteoporosis", Obstet Gynecol Clin North Am, 35(2), pp.301~315 (2008)
- "Clinician's Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation", 19~26 (2008)
- 강병문, "골다골증 치료의 의학약제와 대체 약물의 비교", Obstetrics & Gynecology Science, 49(12), pp.2459~2472 (2006), 대한산부인과학회
- Hamdy RC., "Which central dual Xray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis?", J Clin Densitom, 5, pp.S11~S18 (2002)
- 김덕윤, "골밀도 측정의 올바른 임상 적용", Nuclear Medicine and Molecular Imaging, 38(4), pp.275~281 (2004), 대한핵의학회
- K JM., "The Understanding of Osteoporosis", Drug Information, 31(8), pp.2~6 (2005)
- North American Menopause Society., "Management of osteoporosis in postmenopausal women : 2006 position statement of The North American Menopause Society", Menopause, 13(3), pp.340~367 (2006)